React-Af
Posted Date: Feb 20, 2025
- Investigator: Richard Becker
- Specialties:
- Type of Study: Device
REACT-AF is a multicenter prospective, randomized, open-label, blinded endpoint (PROBE design), controlled trial comparing the current Standard of care of continuous Direct Oral Anticoagulation (DOAC) use versus time-delimited (1 month) DOAC guided by an Atrial Fibrillation sensing smartwatch (apple watch) in participants with a history of non-permanent Atrial Fibrillation and low-to-moderate stroke risk (CHA2DS2-VASc score 1-4 for men, 2-4 for women).
Criteria:
Documented History Of Symptomatic Or Asymptomatic Paroxysmal Or Persistent Atrial Fibrillation
Keywords:
Watch-Triggered Anticoagulation For Afib, “Pill-In-The-Pocket” Approach
For More Information:
Harshada More
5135584739
morehp@ucmail.uc.edu